About US
Contact us
-
Novartis receives FDA approval for Beovu to treat wet AMDNovartis has secured the US Food and Drug Administration (FDA) approval for the use of its Beovu (brolucizumab) medicine to treat wet age-related macular degeneration (AMD). Wet AMD is a degenerative2019/10/9
-
Pfizer licenses Akcea’s ANTPTL3-targetting drug for $250mPfizer and Ionis subsidiary Akcea have signed a global exclusive licensing agreement for antisense therapy AKCEA-ANGPTL3-LRx. According to the terms of the agreement, Akcea and Ionis will receive $252019/10/8
-
UK Government invests £35m into researching adolescent mental healthThe UK Government has launched a research project into understanding the causes of mental health problems in teenagers and young adults, including the genetics and societal influences underpinning wh2019/10/8
-
J&J to invest $500m in HIV and TB therapies researchJohnson & Johnson (J&J) has announced plans to invest over $500m towards research and development of HIV and tuberculosis (TB) vaccines. Set to be used over the coming four years, the investm2019/9/30
-
UK study finds drug that could help treat aggressive breast cancersA study by researchers at The Institute of Cancer Research, London (ICR), has revealed that a drug, BOS172722, could help boost chemotherapy response in aggressive breast cancers that have become res2019/9/30
-
UK study finds drug that could help treat aggressive breast cancersA study by researchers at The Institute of Cancer Research, London (ICR), has revealed that a drug, BOS172722, could help boost chemotherapy response in aggressive breast cancers that have become res2019/9/29
-
FDA approves self-administration of AstraZeneca’s asthma drugThe US Food and Drug Administration (FDA) has approved self-administration AstraZeneca’s asthma drug Fasenra, a pre-filled, single-use auto-injector. The FDA issued its approval based on the Phase II2019/9/29
-
Goldfinch acquires global rights to Takeda’s monoclonal antibodyUS-based clinical-stage biotechnology company Goldfinch Bio has entered an agreement with Japanese firm Takeda Pharmaceutical for global rights to a preclinical, peripherally restricted cannabinoid r2019/9/27
-
ViiV unveils emotional challenges related to HIV ART treatmentGSK’s ViiV Healthcare has presented results from its Positive Perspectives study examining the emotional challenges and burden of human immunodeficiency virus (HIV) antiretroviral therapy (ART) on pe2019/9/27
-
UK’s CMA accuses Aspen of price hike for Addison’s disease drugThe UK’s Competition and Markets Authority (CMA) has alleged that South Africa-based pharmaceutical company Aspen has entered an illegal agreement with Amilco and Tiofarma for marketing Addison’s dis2019/9/26